

We claim:

1. A method of treating a subject suffering from an autoimmune disorder comprising administering to said subject in need of a therapeutically effective amount of a PRMT5 inhibitor.
2. The method of claim 1, wherein the PRMT5 inhibitor is (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharmaceutically acceptable salt thereof.
3. The method of claim 1 or 2, wherein the autoimmune disorder is selected from the group consisting of psoriasis, atopic dermatitis, alopecia areata, ankylosing spondylitis, asthma, type 1 diabetes, multiple sclerosis, celiac disease, scleroderma, hidradenitis suppurativa, vitiligo, dermatomyositis, systemic lupus erythematosus, rheumatoid arthritis, psoriatic arthritis, and inflammatory bowels disease.
4. The method of claim 3, wherein the autoimmune disorder is psoriasis.
5. The method according to any of the preceding claims, wherein said therapeutically effective amount is administered enterally, parenterally, or topically.
6. The method according to claim 5, wherein said enteral administration is administered orally or rectally.
7. The method according to claim 6, wherein said oral administration is administered as a tablet, a capsule, or a liquid dosage form.
8. The method according to claim 5, wherein said parenteral administration is administered intravenously or intraarticularly.
9. The method according to claim 5, wherein said topical administration is administered as a solution, a cream, an ointment, a gel, a lotion, a suspension, or an emulsion.
10. The method according to any of the preceding claims, wherein said subject is administered a therapeutically effective amount from about 0.5 mg to about 120 mg.
11. The method according to claim 10, wherein said therapeutically effective amount is selected from the group consisting of about 0.5 mg, 1 mg, 2 mg, 4 mg, 6 mg, 8mg, 10 mg, 16 mg, 32 mg, 60 mg, 80 mg, and 120 mg.

12. The method according to claim 11, wherein said therapeutically effective amount is about 12 mg.
13. The method according to claim 11, wherein said therapeutically effective amount is about 10 mg.
- 5 14. The method according to claim 11, wherein said therapeutically effective amount is about 8 mg.
15. The method according to claim 11, wherein said therapeutically effective amount is about 6 mg.
- 10 16. The method according to claim 11, wherein said therapeutically effective amount is about 4 mg.
17. The method according to claim 11, wherein said therapeutically effective amount is about 1 mg.
18. The method according to any one of claims 10-17, wherein said therapeutically effective amount is administered once daily (QD).
- 15 19. The method according to any one of claims 10-17, wherein said therapeutically effective amount is administered twice daily (BID).
- 20 20. The method according to any one of claims 2-19, wherein said (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharmaceutically acceptable salt thereof is administered for 1 to 28 days.
21. The method according to any one of claims 2-19, wherein said (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharmaceutically acceptable salt thereof is administered for 1-6 weeks.
- 25 22. The method according to any one of claims 2-19, wherein said (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharmaceutically acceptable salt thereof is administered for 1-6 months.

23. The method according to claim 22, wherein said (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharmaceutically acceptable salt thereof is administered for 1-4 months.